Diabetes, Vol 34, Issue 8 787-792, Copyright © 1985 by American Diabetes Association

ARTICLES

Long-term prognosis after myocardial infarction in men with diabetes

G Ulvenstam, A Aberg, R Bergstrand, S Johansson, K Pennert, A Vedin, L Wilhelmsen and C Wilhelmsson

Men (1306) who survived a first myocardial infarction (MI) were studied. The mean follow-up time was 6.5 yr, and at the end of the follow-up period survival status was known for all patients. By the time of the MI the prevalence of diabetes was 5.6%. Patients with and without diabetes were compared. There were no differences in the estimated primary or secondary risk. The cumulative survival rate 1, 2, and 5 yr after the MI was 82, 78, and 58% among the diabetic subjects compared with 94, 92, and 82% among the nondiabetic subjects (P less than 0.001). The difference remained even after allowance for age and estimated secondary risk in a multivariate regression analysis. There were no differences in mortality rates among patients with type I diabetes compared with type II diabetes, nor among patients treated with diet alone, sulfonylurea, or insulin, but the numbers were small. The cumulative rate of reinfarctions after 1, 2, and 5 yr was 18, 28, and 46% in diabetic subjects and 12, 17, and 27% in nondiabetic subjects (P = 0.004). A history of diabetes was an independent secondary risk factor among male survivors of a first MI with respect to deaths and reinfarctions.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. van Lunteren and M. Moyer Oxidoreductase, morphogenesis, extracellular matrix, and calcium ion-binding gene expression in streptozotocin-induced diabetic rat heart Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E759 - E768. [Abstract] [Full Text] [PDF]

				H. Zhou, D. J.M. Isaman, S. Messinger, M. B. Brown, R. Klein, M. Brandle, and W. H. Herman A Computer Simulation Model of Diabetes Progression, Quality of Life, and Cost Diabetes Care, December 1, 2005; 28(12): 2856 - 2863. [Abstract] [Full Text] [PDF]

				M. Srinivasan, P. Herrero, J. B. McGill, J. Bennik, B. Heere, D. Lesniak, V. G. Davila-Roman, and R. J. Gropler The Effects of Plasma Insulin and Glucose on Myocardial Blood Flow in Patients With Type 1 Diabetes Mellitus J. Am. Coll. Cardiol., July 5, 2005; 46(1): 42 - 48. [Abstract] [Full Text] [PDF]

				M. Cusick, A. D. Meleth, E. Agron, M. R. Fisher, G. F. Reed, G. L. Knatterud, F. B. Barton, M. D. Davis, F. L. Ferris III, E. Y. Chew, et al. Associations of Mortality and Diabetes Complications in Patients With Type 1 and Type 2 Diabetes: Early Treatment Diabetic Retinopathy Study report no. 27 Diabetes Care, March 1, 2005; 28(3): 617 - 625. [Abstract] [Full Text] [PDF]

				A. M. Murcia, C. H. Hennekens, G. A. Lamas, M. Jimenez-Navarro, J. L. Rouleau, G. C. Flaker, S. Goldman, H. Skali, E. Braunwald, and M. A. Pfeffer Impact of Diabetes on Mortality in Patients With Myocardial Infarction and Left Ventricular Dysfunction Arch Intern Med, November 8, 2004; 164(20): 2273 - 2279. [Abstract] [Full Text] [PDF]

				K. Franklin, R. J. Goldberg, F. Spencer, W. Klein, A. Budaj, D. Brieger, M. Marre, P. G. Steg, N. Gowda, J. M. Gore, et al. Implications of Diabetes in Patients With Acute Coronary Syndromes: The Global Registry of Acute Coronary Events Arch Intern Med, July 12, 2004; 164(13): 1457 - 1463. [Abstract] [Full Text] [PDF]

				P L Sanchez, J L Morinigo, P Pabon, F Martin, I Piedra, I F Palacios, and C Martin-Luengo Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome Heart, March 1, 2004; 90(3): 264 - 269. [Abstract] [Full Text] [PDF]

				J J Meier, B Gallwitz, W E Schmidt, A Mugge, and M A Nauck Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart, January 1, 2004; 90(1): 9 - 12. [Abstract] [Full Text] [PDF]

				D. Chyun, V. Vaccarino, J. Murillo, L. H. Young, and H. M. Krumholz Cardiac Outcomes After Myocardial Infarction in Elderly Patients With Diabetes Mellitus Am. J. Crit. Care., November 1, 2002; 11(6): 504 - 519. [Abstract] [Full Text] [PDF]

				L Wilhelmsen, K Pyorala, H Wedel, T Cook, T Pedersen, J Kjekshus, and for the 4S Study Group Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment Eur. Heart J., July 1, 2001; 22(13): 1119 - 1127. [Abstract] [PDF]

				A Klamann, P Sarfert, V Launhardt, G Schulte, W.H Schmiegel, and M.A Nauck Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide) Eur. Heart J., February 1, 2000; 21(3): 220 - 229. [Abstract] [PDF]

				R. Williams, B M. Fisher, and K. McLaughlin Intensive insulin treatment after acute myocardial infarction in diabetes mellitus BMJ, August 30, 1997; 315(7107): 544 - 544. [Full Text]

				K. Malmberg Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus BMJ, May 24, 1997; 314(7093): 1512 - 1512. [Abstract] [Full Text]

				R. L. Engler and D. M. Yellon Sulfonylurea KATP Blockade in Type II Diabetes and Preconditioning in Cardiovascular Disease: Time for Reconsideration Circulation, November 1, 1996; 94(9): 2297 - 2301. [Full Text]